Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
With one gene therapy for hemophilia B well along the way in the clinic at Spark Therapeutics, pharma giant Pfizer $PFE is now extending its interest in the field with a pact with Sangamo on a new gene therapy for hemophilia A.
The exclusive worldwide licensing deal on four programs at the longtime gene therapy biotech includes SB-525, which is poised on the threshold of a clinical trial.
“Pfizer has made significant investments in gene therapy over the last few years and we are building an industry-leading expertise in recombinant adeno-associated virus (rAAV) vector design and manufacturing,” noted Pfizer R&D chief Mikael Dolsten.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.